Wedbush Raises Earnings Estimates for Viridian Therapeutics

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Investment analysts at Wedbush upped their Q1 2025 EPS estimates for Viridian Therapeutics in a research note issued on Thursday, February 27th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($1.01) for the quarter, up from their prior forecast of ($1.02). The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. Wedbush also issued estimates for Viridian Therapeutics’ Q2 2025 earnings at ($1.04) EPS, Q3 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at ($4.03) EPS, FY2026 earnings at ($4.43) EPS and FY2029 earnings at $11.84 EPS.

Other analysts also recently issued research reports about the stock. TD Cowen started coverage on shares of Viridian Therapeutics in a research report on Monday, November 25th. They set a “buy” rating for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. Royal Bank of Canada upped their price objective on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Tuesday, December 17th. HC Wainwright restated a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research note on Monday, December 16th. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and set a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $35.70.

Viridian Therapeutics Trading Down 7.2 %

Shares of VRDN stock opened at $14.41 on Monday. Viridian Therapeutics has a fifty-two week low of $11.40 and a fifty-two week high of $27.20. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The stock has a 50 day simple moving average of $18.10 and a two-hundred day simple moving average of $19.70. The company has a market cap of $1.14 billion, a P/E ratio of -3.34 and a beta of 1.32.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The firm had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.05 million.

Hedge Funds Weigh In On Viridian Therapeutics

Large investors have recently bought and sold shares of the stock. R Squared Ltd purchased a new stake in shares of Viridian Therapeutics in the fourth quarter valued at about $26,000. Foresite Capital Management VI LLC bought a new stake in Viridian Therapeutics in the 4th quarter worth about $38,000. AlphaQuest LLC increased its stake in Viridian Therapeutics by 119.0% in the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after buying an additional 1,519 shares during the last quarter. Summit Investment Advisors Inc. lifted its position in shares of Viridian Therapeutics by 24.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company’s stock worth $147,000 after buying an additional 1,516 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Viridian Therapeutics during the 3rd quarter worth approximately $149,000.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.